These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28939995)

  • 1. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Hydrogen Exchange Mass Spectrometry as a Stability-Indicating Method for Formulation Excipient Screening for an IgG4 Monoclonal Antibody.
    Toth RT; Pace SE; Mills BJ; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2018 Apr; 107(4):1009-1019. PubMed ID: 29269271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
    Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
    MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
    Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
    J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.
    Ishikawa T; Ito T; Endo R; Nakagawa K; Sawa E; Wakamatsu K
    Biol Pharm Bull; 2010; 33(8):1413-7. PubMed ID: 20686240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations.
    Chavez BK; Agarabi CD; Read EK; Boyne MT; Khan MA; Brorson KA
    Biomed Res Int; 2016; 2016():2074149. PubMed ID: 27042659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
    Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
    J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis.
    He F; Woods CE; Trilisky E; Bower KM; Litowski JR; Kerwin BA; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Apr; 100(4):1330-40. PubMed ID: 24081468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brij-58, a potential injectable protein-stabilizer used in therapeutic protein formulation.
    Yue L; Yan Z; Li H; Liu X; Sun P
    Eur J Pharm Biopharm; 2020 Jan; 146():73-83. PubMed ID: 31811896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
    Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Novel Bispecific Antibody With Improved Conformational and Chemical Stability.
    Manikwar P; Mulagapati SHR; Kasturirangan S; Moez K; Rainey GJ; Lobo B
    J Pharm Sci; 2020 Jan; 109(1):220-232. PubMed ID: 31288034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matching pH values for antibody stabilization and crystallization suggest rationale for accelerated development of biotherapeutic drugs.
    Sjuts H; Schreuder H; Engel CK; Bussemer T; Gokarn Y
    Drug Dev Res; 2020 May; 81(3):329-337. PubMed ID: 31758731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Approach to Study the Physical Stability of Monoclonal Antibody Formulations-Dilution From a Denaturant.
    Svilenov H; Gentiluomo L; Friess W; Roessner D; Winter G
    J Pharm Sci; 2018 Dec; 107(12):3007-3013. PubMed ID: 30121313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface activity of a monoclonal antibody.
    Mahler HC; Senner F; Maeder K; Mueller R
    J Pharm Sci; 2009 Dec; 98(12):4525-33. PubMed ID: 19655376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.